BACKGROUND
Proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab reduced the risk of a first major adverse cardiovascular event (MACE) in patients at high cardiovascular risk with no prior myocardial infarction (MI) or stroke in the VESALIUS-CV (Effect of Evolocumab in Patients at High Cardiovascular...
José C. Nicolau, Sabina A. Murphy, Robert P. Giugliano et al.· Journal of the American Coll...· 1 citation
BACKGROUND
Evolocumab, a PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor, significantly reduced the risk of cardiovascular events in patients without previous myocardial infarction or stroke in the VESALIUS-CV trial (Effect of Evolocumab in Patients at High Cardiovascular Risk without Prior Myocardial I...
Robert P. Giugliano, E. Bohula, A. Bellavia et al.· Circulation· 0 citations
BACKGROUND
Real-world evidence on lipid-lowering therapy (LLT) use and low-density lipoprotein cholesterol (LDL-C) control in patients at high cardiovascular (CV) risk without prior myocardial infarction (MI) or stroke remains limited. We evaluated LLT use, treatment intensification, LDL-C monitoring, and LDL-C goal at...
Q. Chan, J. Cegla, U. Laufs et al.· Clinical Research in Cardiol...· 0 citations
It is argued that current evaluation paradigms inadequately capture the uncertainty-intensive nature of athlete cardiovascular assessment and proposed the text-proxy paradigm, a governance-oriented framework in which LLMs operate as semantic integration layers that process clinician-verified and structured outputs gene...
Stefano Palermi, A. Saglietto, F. d'Ascenzo et al.· Progress in cardiovascular d...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.